New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
This chapter focuses on new antithrombotic drugs that are in phase II or III clinical testing. Development of these new agents was prompted by limitations of existing antiplatelet, anticoagulant, or fibrinolytic drugs. Addressing these unmet needs, this chapter (1) outlines the rationale for development of new antithrombotic agents, (2) describes the new antiplatelet, anticoagulant, and fibrinolytic drugs, and (3) provides clinical perspectives on the opportunities and challenges faced by these novel agents.
From the Henderson Research Center, McMaster University, Hamilton, ON, Canada. Electronic address: jweitz@thrombosis.hhscr.org.
Jeffrey I
JI
Weitz
From the Henderson Research Center, McMaster University, Hamilton, ON, Canada.
Jack
J
Hirsh
Hôtel-Dieu University Hospital, Paris, France.
Meyer M
MM
Samama
D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D015507:Drugs, Investigational; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D015912:Thrombolytic Therapy
D015507:Drugs, Investigational; D005343:Fibrinolytic Agents